During Digestive Disease Week 2019, held May 18-21 in San Diego, California, researchers presented the 1-year results of a phase 1 trial of subcutaneous CT-P13 versus the intravenous formulation of the biosimilar in patients with Crohn disease (CD).
Celltrion’s proposed subcutaneous formulation of its infliximab biosimilar, CT-P13 (Remsima, Inflectra) is currently under European Medicines Agency evaluation, and the proposed formulation of the drug will also be studied in the United States in a phase 3 program in patients with inflammatory bowel disease.
During Digestive Disease Week 2019, held May 18-21 in San Diego, California, researchers presented the 1-year results of a phase 1 trial of subcutaneous CT-P13 versus the intravenous formulation of the biosimilar in patients with Crohn disease (CD).1
Patients (n = 44) who had moderate to severe CD—defined as a Crohn Disease Activity Index score of 220 to 450—were given IV CT-P13 at 5 mg/kg at weeks 0 and 2, then randomized into 4 cohorts of 11 patients each.
One cohort continued to receive the IV biosimilar every 8 weeks, while the second, third, and fourth cohorts each received the subcutaneous biosimilar at doses of 120 mg, 180 mg, and 240 mg, respectively, every 2 weeks up to week 54.
At week 30, overall clinical response rates among cohorts were similar. Clinical remission was numerically higher in the subcutaneous therapy cohorts at week 54 (8 patients, 7 patients, and 4 patients in the respective subcutaneous groups versus 4 patients in the IV group).
The mean predose serum concentration of infliximab before the next dose was higher in the subcutaneous cohorts throughout the study versus the IV group. Ctrough levels increased as the subcutaneous dose increased, and were substantially higher than the target therapeutic concentration.
The safety profiles of the IV and subcutaneous formulations were comparable, and 11.4% of patients had injection-site reactions, all in the subcutaneous administration group.
The authors concluded that the novel formulation of the biosimilar infliximab had similar efficacy and safety to the IV formulation at 1 year, and that this formulation could expand treatment options for patients with CD by providing high consistency in drug exposure during maintenance therapy.
In addition to making an appealing choice for patients who are satisfied with treatment with intravenous infliximab but who prefer or need a subcutaneous route of administration, the new formulation of CT-P13, said Celltrion in a recent statement, could compete with brand-name adalimumab (Humira), another subcutaneously administered anti—tumor necrosis factor therapy.
Reference
1. Byong DY, Byung IJ, Borzan V, et al. A novel formulation of CT-P13 (infliximab biosimilar) for subcutaneous administration: 1-year result from a phase 1 open-label randomized controlled trial in patients with active Crohn’s disease. Presented at: Digestive Disease Week 2019, San Diego, California, May 18-21, 2019. Abstract Tu1715.
Physician and Patient Perspectives After Starting or Switching to Amgevita in IBD
March 23rd 2024A real-world study surveying physicians and patients on adalimumab biosimilar ABP 501 (Amgevita) in inflammatory bowel disease (IBD) found both patients initiating ABP 501 and those who had switched from the reference product had higher satisfaction levels.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Webinar Addresses Solutions to Improve Adalimumab Biosimilar Uptake
March 18th 2024Government policies, including those related to prescribing incentives and interchangeability, need to be reworked to encourage biosimilar adoption and create meaningful savings for health systems, according to speakers at a recent webinar.
Biosimilars Gastroenterology Roundup for January 2024—Podcast Edition
February 4th 2024On this episode of Not So Different, we reminisce on all the major gastroenterology news from January, which brought several reports quantifying how the gastroenterology biosimilar market is progressing and marked the 1-year anniversary of adalimumab biosimilar competition in the US.
Review: Real-World Evidence Confirms Effectiveness and Safety of Adalimumab Biosimilar SB5
March 9th 2024The adalimumab biosimilar SB5 was reported to be as safe and effective as the reference product in a review of randomized controlled trials and real-world studies on immune-mediated inflammatory diseases.